# Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

> **NCT01903733** · NA · COMPLETED · sponsor: **Pfizer** · enrollment: 281 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** bosutinib

## Key facts

- **NCT ID:** NCT01903733
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-28
- **Primary completion:** 2020-06-05
- **Final completion:** 2020-06-05
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01903733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01903733, "Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01903733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*